JDD March 2024 Issue Highlights
213712137121371
March into groundbreaking dermatological insights with the latest issue of the Journal of Drugs in Dermatology! Explore the prescribing habits of oral minoxidil for androgenetic alopecia, delve into a comprehensive review of botulinum toxin uses, and discover the effectiveness of microneedling for acne scars. Plus, unravel the uncertainties surrounding exosome therapy in androgenetic alopecia. Fro …
March into groundbreaking dermatological insights with the latest issue of the Journal of Drugs in Dermatology! Explore the prescribing habits of oral minoxidil for androgenetic alopecia, delve into a comprehensive review of botulinum toxin uses, and discover the effectiveness of microneedling for acne scars. Plus, unravel the uncertainties surrounding exosome therapy in androgenetic alopecia. Fro … 
Pretibial myxedema (PTM) is a rare complication of Graves' disease. It is characterized by non-pitting edema with hyperpigmented hyperkeratotic papules and plaques on bilateral lower legs. Effective treatments for patients with PTM are lacking. The etiology of PTM is unknown; however, it may be similar to the mechanism of thyroid-associated ophthalmopathy (TAO). Activated fibroblasts produce infla … 
JDD authors Mihir Shah MD, Jenna Wald MD, and C. William Hanke MD MPH present a case of a patient with eruptive squamous cell carcinomas following treatment with Fludarabine to highlight not only the risk of cSCC in CLL patients and the increased risk for atypical cutaneous malignancies after treatment with systemic therapies such as fludarabine, but also to discuss treatment options for this … 
At ODAC 2023, we had the opportunity to learn about the latest in treatments for blistering diseases from Dr. Karl Saardi, Associate Professor and Director of Inpatient Dermatology at George Washington University. We focused on the pemphigus and pemphigoid group of diseases, which we will review and summarize here.
Pemphigus
The pemphigus group of diseases is characterized by intraepidermal auto … 
Rituximab was the first monoclonal antibody approved for cancer treatment and now in dermatology, this medication has been life-altering for patients with the severe, autoimmune blistering disease, pemphigus vulgaris. We continue our series, Therapeutic Cheat Sheet, with a closer look at rituximab, which is FDA-approved for the treatment of pemphigus vulgaris, and is also used off label for other … 